Immediate Impact

1 from Science/Nature 70 standout
Sub-graph 1 of 24

Citing Papers

New epilepsy therapies in development
2024 Standout
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele
2023 Standout
8 intermediate papers

Works of P. Masel being referenced

Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection
2004
Nebulised dornase alpha: adherence in adults with cystic fibrosis
2002

Author Peers

Author Last Decade Papers Cites
P. Masel 137 24 3 39 29 19 186
Alastair Reid 174 41 28 19 25 14 263
Kay Tyerman 80 19 47 25 16 20 247
Bryan Garcia 143 16 41 91 18 17 251
Xingqi Deng 68 59 18 93 18 15 266
Vesna Čukić 153 70 26 24 26 24 276
Hiroshi Kawane 100 74 28 88 20 22 254
Satish Haridasan 31 34 14 39 28 24 233
Yong‐Kek Pang 135 29 17 73 39 21 248
Rik De Decker 142 32 51 79 11 23 261
Han-Pin Kuo 119 61 57 64 39 17 276

All Works

Loading papers...

Rankless by CCL
2026